# OnCo record nct02711553 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02711553/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02711553", "NCT02711553" ;
  schema:name "A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer"@en ;
  schema:description "A phase 2 trial of Ramucirumab, Cisplatin, Gemcitabine in metastatic cancer, run by Eli Lilly and Company, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct02711553/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02711553> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2016-05-19" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/merestinib/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> .